SCHEMBL19519829

SCHEMBL19519829

Cc1c(C(=O)NCc2ccccc2)c(=O)n(O)c2ncccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.47
KDM4E B2RXH2 2/20 0.47
MEN1 O00255 1/20 0.47
RAB9A P51151 1/20 0.47
KMT2A Q03164 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
NSD2 O96028 1/20 0.47
LIPG Q9Y5X9 1/20 0.46
ADORA2A P29274 1/20 0.46
ALDH1A1 P00352 3/20 0.46
POLB P06746 2/20 0.46
PKM P14618 1/20 0.46
MAPT P10636 2/20 0.46
TP53 P04637 1/20 0.46
LMNA P02545 2/20 0.46
EGFR P00533 1/20 0.46
SRC P12931 1/20 0.46
RXFP1 Q9HBX9 1/20 0.45
PIK3CD O00329 1/20 0.45
GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3517727 0.87 MEN1 (0.57) NPC1KDM4EMEN1RAB9AKMT2A
SCHEMBL19519830 0.84 MAPT (0.44) NPC1KDM4EMEN1RAB9AKMT2A
SCHEMBL13461640 0.78 MEN1 (0.55) NPC1KDM4EMEN1RAB9AKMT2A
SCHEMBL3514915 0.77 KMT2A (0.58) NPC1MEN1RAB9AKMT2AL3MBTL1
SCHEMBL3519483 0.76 SMN1; SMN2 (0.47) KDM4EMEN1RAB9AKMT2AL3MBTL1
SCHEMBL18950173 0.75 CNR1 (0.57) KDM4EKMT2ANSD2ADORA2AALDH1A1
SCHEMBL15168245 0.75 MEN1 (0.54) NPC1KDM4EMEN1RAB9AKMT2A
SCHEMBL15170521 0.74 NPC1 (0.50) NPC1KDM4EMEN1RAB9AKMT2A
SCHEMBL3516261 0.74 MEN1 (0.53) NPC1KDM4EMEN1RAB9AKMT2A
SCHEMBL9045284 0.74 MEN1 (0.55) NPC1KDM4EMEN1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10208035-B2 Compounds for inhibiting drug-resistant strains of HIV-1 integrase THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2019-02-19 US disclosed
US-20170305904-A1 COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) 2017-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10208035-B2 Compounds for inhibiting drug-resistant strains of HIV-1 integrase CCR8, CDK8, CHD8 NPC1 716/4885KDM4E 1233/4885MEN1 4337/4885
US-20170305904-A1 COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE CCR8, CDK8, CHD8 NPC1 716/4885KDM4E 1233/4885MEN1 4337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.